Your browser is no longer supported. Please, upgrade your browser.
Settings
PTPI [NASD]
Petros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.19 Insider Own36.74% Shs Outstand9.75M Perf Week-4.40%
Market Cap29.73M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.20M Perf Month-2.88%
Income-11.50M PEG- EPS next Q- Inst Own9.50% Short Float2.59% Perf Quarter-5.59%
Sales11.80M P/S2.52 EPS this Y36.70% Inst Trans-2.11% Short Ratio0.72 Perf Half Y-9.52%
Book/sh2.15 P/B1.41 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh1.49 P/C2.04 EPS next 5Y- ROE- 52W Range1.80 - 5.96 Perf YTD-30.91%
Dividend- P/FCF- EPS past 5Y- ROI-64.20% 52W High-48.99% Beta-
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin67.00% 52W Low68.89% ATR0.19
Employees27 Current Ratio0.60 Sales Q/Q-73.70% Oper. Margin- RSI (14)46.19 Volatility7.10% 5.45%
OptionableYes Debt/Eq0.24 EPS Q/Q109.20% Profit Margin- Rel Volume0.30 Prev Close3.01
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume221.70K Price3.04
Recom- SMA20-1.80% SMA50-3.67% SMA200-12.36% Volume66,583 Change1.00%
Jul-27-21 09:25AM  
Jul-13-21 09:15AM  
Jul-12-21 08:15AM  
Jun-02-21 10:12AM  
May-17-21 08:22AM  
May-14-21 08:30AM  
May-07-21 08:00AM  
Mar-18-21 09:00AM  
Feb-18-21 08:00AM  
Feb-04-21 08:30AM  
Jan-19-21 08:00AM  
Dec-08-20 04:15PM  
Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.